CRISPR-Cas12

CRISPR-Cas12
Name	CRISPR-Cas12
Type	Genome editing endonuclease
Purpose	Targeted nucleic acid cleavage and diagnostics

CRISPR-Cas12 is a family of RNA-guided endonucleases used for targeted DNA and single-stranded DNA cleavage in prokaryotic adaptive immunity and biotechnology. It complements other programmable nucleases by providing distinct protospacer adjacent motif (PAM) recognitions, single- or double-strand cleavage modalities, and collateral single-stranded DNase activity exploited for diagnostics. Prominent for its utility in molecular detection, therapeutic research, and agricultural engineering, Cas12 enzymes have been integrated into platforms that engage institutions and figures across academic and industrial settings.

Introduction

Cas12 enzymes originate from diverse bacterial and archaeal taxa and were characterized amid a broader effort that involved labs associated with the Broad Institute, University of California, Berkeley, Massachusetts Institute of Technology, Harvard University, and biotech companies such as Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics. The proteins are distinct from class 2 effectors like those associated with SpCas9, and have been studied in contexts involving researchers affiliated with awards and institutions such as the Nobel Prize, Howard Hughes Medical Institute, and collaborations with organizations like Bill & Melinda Gates Foundation. Early and translational work connected investigators from universities including Stanford University, University of Pennsylvania, University of Cambridge, and Johns Hopkins University.

Classification and Mechanism

Cas12 proteins belong to class 2, type V CRISPR systems, alongside subtypes such as V-A, V-B, V-C, and related families discovered in microbial surveys including contributions from groups at Joint Genome Institute and European Molecular Biology Laboratory. Structurally, Cas12 orthologs display distinct RuvC nuclease domains that mediate cleavage, and engage CRISPR RNAs processed by enzymes from loci studied by researchers at Max Planck Institute and Wellcome Trust Sanger Institute. Target recognition depends on PAM sequences that vary among orthologs—comparative analyses referenced by teams at California Institute of Technology, Scripps Research Institute, and Cold Spring Harbor Laboratory revealed PAM-dependent binding and R-loop formation similar in conceptual terms to mechanisms characterized in other systems researched at Yale University and University of Chicago. Upon target binding, many Cas12 enzymes execute a staggered double-strand break or nicking cleavage and can acquire non-specific single-stranded DNase activity, a property distinguished from the double-strand-specific cleavage of effectors associated with SpCas9-related studies at University of Oxford.

Applications in Genome Editing and Diagnostics

Cas12-based nucleases have been adapted for precise genome modifications in systems used by labs at UC San Diego, University of Wisconsin–Madison, Cold Spring Harbor Laboratory, and translational teams at Genentech and Novartis. Applications include targeted gene disruption, base editing scaffolds developed in collaborations involving Broad Institute affiliates, and integration with repair templates for homology-directed repair trials conducted at institutions like Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Diagnostic platforms harnessing collateral ssDNase activity were commercialized and refined by startups and consortia linked to MIT Media Lab, Harvard Medical School, and public health agencies such as Centers for Disease Control and Prevention and World Health Organization collaborations during outbreak responses. Notable implementations paralleled efforts involving Bill Gates-funded initiatives and public–private partnerships with companies like Abbott Laboratories and Thermo Fisher Scientific to develop point-of-care tests and environmental surveillance assays.

Delivery Methods and Engineering

Efficient deployment of Cas12 effectors into cells and organisms has been pursued using viral vectors studied at Emory University and University of California, Los Angeles, non-viral nanoparticles engineered by teams at MIT, lipid formulations from researchers at University of Pennsylvania and groups working with Alnylam Pharmaceuticals, and physical methods such as electroporation and microinjection routinely used at Rockefeller University and Cold Spring Harbor Laboratory. Protein engineering to alter PAM specificity, reduce size for adeno-associated virus (AAV) packaging, or attenuate collateral activity drew on directed evolution platforms developed at Broad Institute, rational design paradigms employed by Harvard University groups, and high-throughput screening resources at European Molecular Biology Laboratory and Sanger Institute.

Off-target Effects, Safety, and Ethical Considerations

Assessment of off-target cleavage and genomic integrity has been a focus of safety studies at National Institutes of Health, Food and Drug Administration, and academic centers including University of California, San Francisco and Karolinska Institute. Strategies to mitigate unintended edits include high-fidelity variants engineered by teams at Broad Institute and Stanford University, transient delivery approaches trialed with collaborators at Massachusetts General Hospital, and orthogonal control systems developed using synthetic biology frameworks from ETH Zurich and Imperial College London. Ethical debates surrounding human germline editing, somatic therapies, and agricultural deployment have engaged stakeholders including Nuffield Council on Bioethics, National Academy of Sciences, and policy discussions referenced in forums like United Nations and regional regulatory bodies such as the European Commission.

History and Discovery

The discovery trajectory for Cas12 was embedded in the broader history of CRISPR research originating from foundational work by groups at University of Alicante, University of Copenhagen, University of Vienna, and early microbial CRISPR characterization by teams associated with GenBank sequence repositories and metagenomic surveys coordinated through institutions such as Joint Genome Institute and European Nucleotide Archive. Subsequent biochemical and structural elucidation involved collaborations across Max Planck Institute for Developmental Biology, Riken, and laboratories enabled by funding from agencies like Wellcome Trust and National Science Foundation, culminating in the recognition of Cas12 as a versatile tool across basic and applied biosciences.

Category:Genome editing